Fate Therapeutics Stock Performance
| FATE Stock | USD 1.12 0.03 2.75% |
The firm shows a Beta (market volatility) of 2.61, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fate Therapeutics will likely underperform. At this point, Fate Therapeutics has a negative expected return of -1.41%. Please make sure to confirm Fate Therapeutics' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Fate Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Fate Therapeutics Announces Leadership Transition | 11/29/2024 |
2 | Disposition of 56331 shares by Redmile Group, Llc of Fate Therapeutics at 3.02 subject to Rule 16b-3 | 12/20/2024 |
3 | Redmile Group, LLC Reduces Stake in Fate Therapeutics Inc | 12/27/2024 |
4 | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 | 01/03/2025 |
5 | Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting... | 01/07/2025 |
6 | Disposition of 8705 shares by Bahram Valamehr of Fate Therapeutics at 1.54 subject to Rule 16b-3 | 01/10/2025 |
7 | Fate Therapeutics SWOT analysis stock poised for growth amid clinical progress | 01/14/2025 |
8 | Acquisition by Bahram Valamehr of 1300000 shares of Fate Therapeutics at 1.25 subject to Rule 16b-3 | 01/16/2025 |
9 | Disposition of 6022 shares by Redmile Group, Llc of Fate Therapeutics subject to Rule 16b-3 | 01/31/2025 |
10 | Were Keeping An Eye On Fate Therapeutics Cash Burn Rate | 02/04/2025 |
11 | Acquisition by Dulac Edward J Iii of 425000 shares of Fate Therapeutics at 6.77 subject to Rule 16b-3 | 02/28/2025 |
| Begin Period Cash Flow | 76.6 M |
Fate |
Fate Therapeutics Relative Risk vs. Return Landscape
If you would invest 296.00 in Fate Therapeutics on December 1, 2024 and sell it today you would lose (184.00) from holding Fate Therapeutics or give up 62.16% of portfolio value over 90 days. Fate Therapeutics is currently does not generate positive expected returns and assumes 6.3446% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Fate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fate Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fate Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fate Therapeutics, and traders can use it to determine the average amount a Fate Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2216
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FATE |
Estimated Market Risk
| 6.34 actual daily | 56 56% of assets are less volatile |
Expected Return
| -1.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fate Therapeutics by adding Fate Therapeutics to a well-diversified portfolio.
Fate Therapeutics Fundamentals Growth
Fate Stock prices reflect investors' perceptions of the future prospects and financial health of Fate Therapeutics, and Fate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fate Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (17.04) % | ||||
| Current Valuation | (73.23 M) | ||||
| Shares Outstanding | 113.89 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 0.34 X | ||||
| Price To Sales | 9.49 X | ||||
| Revenue | 63.53 M | ||||
| Gross Profit | (108.86 M) | ||||
| EBITDA | (172.23 M) | ||||
| Net Income | (160.93 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 103.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 3.18 X | ||||
| Cash Flow From Operations | (132.26 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 127.56 M | ||||
| Total Asset | 506.22 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 292.45 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
About Fate Therapeutics Performance
By analyzing Fate Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fate Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fate Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fate Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.50) | (0.53) |
Things to note about Fate Therapeutics performance evaluation
Checking the ongoing alerts about Fate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fate Therapeutics generated a negative expected return over the last 90 days | |
| Fate Therapeutics has high historical volatility and very poor performance | |
| Fate Therapeutics may become a speculative penny stock | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (108.86 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Dulac Edward J Iii of 425000 shares of Fate Therapeutics at 6.77 subject to Rule 16b-3 |
- Analyzing Fate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fate Therapeutics' stock. These opinions can provide insight into Fate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |